Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds – San Diego Biotechnology Network
Summary
Calidi Biotherapeutics announced a warrant exercise that will bring in about $4.6 million in gross proceeds. The company agreed to an immediate exercise of several outstanding warrant series at a reduced price of $0.70 per share. The transaction covers up to 6,595,000 shares of common stock. Calidi is a clinical-stage biotechnology company focused on targeted therapies for genetic medicines.
Funding
Amount
$4.6M
Total raised
Date
July 9, 2025
Announcement date
Investors
-
Lead investors
Company
calidibio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected